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Introduction
Growing evidence indicates that carcinomas, the most common
and lethal of human tumors, may be mechanistically more com-
plex than originally thought. Although it is well established that
most carcinomas arise from the stepwise accumulation of genet-
ic changes (Hahn and Weinberg, 2002), the nature and temporal
sequence of such changes is less clear. Cancers in general, and
carcinomas in particular, exhibit extensive modifications in
genome composition, ranging from subtle point mutations to dra-
matic gains and losses of genetic material (aneuploidy). Though
the role of mutations in tumorigenesis has gained strength, ever
since Hermann J. Muller proposed that multiple intragenic muta-
tions can cause cancer (Muller, 1927), the contribution of aneu-
ploidy is less certain and hotly debated (Marx, 2002). This
debate has reignited an old controversy concerning the domi-
nance of mutations or aneuploidy as the cause of cancer, and
has polarized the research community into espousing either one
or the other pathway as being both necessary and sufficient for
cancer development (Hahn and Weinberg, 2002; Li et al., 2000;
Marx, 2002). Here we review recent experimental evidence that
argues strongly for collaboration between intragenic mutations
(referred to as mutations from this point on) and aneuploidy in
the pathogenesis of carcinoma.
Mutations and cancer
Gatekeeper genes that control cell growth and death and care-
taker genes that maintain genome integrity are the most com-
mon genes implicated in cancer (Kinzler and Vogelstein, 1997).
Members of either class can act as oncogenes (OG) when acti-
vated by gain of function mutations (e.g., ras, Flt-3, c-kit) or
tumor suppressor genes (TSG) when inactivated by loss of
function mutations (e.g., p53, Rb, APC) (Weinberg, 1994).
Intragenic mutations in cancer accrue in a small subset
of genes
Lawrence Loeb originally postulated that tumor development
required cells to acquire a high mutation rate (Loeb, 1991).
However, more than thirty years of research has failed to pro-
vide compelling support for such a “cancer mutator phenotype”
(Marx, 2002), with a few remarkable exceptions (Modrich and
Lahue, 1996). Recently, direct measurements of mutations in
sporadic colon carcinoma showed that the total number of
mutations was considerably lower than predicted by Loeb’s
model (Wang et al., 2002) and suggested that increased gene
mutation rate alone may not be the key to cancer. Moreover,
mutations that occur during development of most sporadic
human carcinomas are restricted to a small subset of genes,
including components of the ras (Sahai and Marshall, 2002),
p53 (Levine et al., 1991), Rb (Sherr and McCormick, 2002), Akt
(Vivanco and Sawyers, 2002), and Wnt (Taipale and Beachy,
2001) signal transduction pathways (Hunter, 1997).
Role of cell proliferation in cancer gene mutation accrual
If the rate of point mutation in cancer is not markedly increased,
how can mutations arise in such a restricted set of genes at
apparently high rates? The most likely mechanism is that preva-
lent cancer point mutations confer significant proliferative
and/or survival advantages, allowing cells carrying them to
quickly become the dominant cell population within a tissue
(Tomlinson et al., 1996). Viewed in this context, rapid accrual of
mutations in cancer genes driven primarily by increased cell
proliferation becomes plausible even in the absence of an
increased frequency of total mutations. Selective accrual of
mutations could also occur as a result of chemical or physical
mutagenesis, provided the mutation rate is low, thus enabling
cell proliferation to exert a dominant effect on mutational accru-
al (Tomlinson et al., 1996). Given the potential of cell prolifera-
tion to promote accrual of mutations and tumorigenesis, it is not
surprising that multicellular organisms have evolved robust
mechanisms to set limits to proliferation potential in somatic
cells. The most important of these checkpoint mechanisms are
cell cycle arrest and apoptosis triggered by telomere erosion
(Chin et al., 1999). In fact, telomere integrity appears to be a
critical element in cancer development (see below).
Aneuploidy and CIN in cancer
The majority of carcinomas exhibit unstable aneuploidy. Cells
within the same tumor characteristically bear striking differ-
ences in chromosome number that appear to arise from contin-
uous losses and gains of chromosomes during mitosis (Figure
1) (Jallepalli and Lengauer, 2001). Tumor cells also exhibit
ongoing and apparently stochastic large-scale structural
changes such as nonreciprocal translocations, inversions, dele-
tions, insertions, and other types of transpositions of chromo-
some material. These prevalent numerical and structural forms
of genome plasticity, hereafter referred to collectively as chro-
mosome instability (CIN), occur continuously and lead to exten-
sive “genome scrambling.” In contrast to carcinomas, leukemias
and lymphomas do not exhibit extensive CIN (Heim and
Mitelman, 1995). They are often diploid or near diploid and
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when aneuploid, exhibit relatively stable chromosome comple-
ments. This is probably because aneuploidy in lymphoma and
leukemia more likely arises as a rare event in a tumor founder
cell. What then could be the pathogenic role of CIN in human
carcinoma?
Formulated by Boveri a century ago, the so called “aneu-
ploidy theory” of cancer origin has fallen out of favor. This is a
consequence of our increased understanding of the molecu-
lar biology of cancer, persuasive literature supporting the
idea that gene mutation drives tumorigenesis (Balmain,
2001), and the conceptual influence of the identification of a
handful of frequently mutated genes in cancer (notably ras,
p53, Rb, AKT, PTEN, p16INK4a, and Wnt). However, our cur-
rent concept of cancer has overlooked the central idea in
Boveri’s proposal. In essence, Boveri proposed that cancer
arose by gains and/or loses of growth-promoting and growth-
restraining genes, respectively. He pointed out that rare
abnormal mitoses could lead to the “right combination of
chromatin determinants” which could unleash cancer
(Balmain, 2001). At a time when the concept of “gene” was
still being developed in his laboratory (Balzer, 1967), Boveri
was the first to propose that acquisition of the appropriate
combination of genes (“chromatin determinants”) (Boveri,
1914), now known as gene dosage effects, played a role in
cancer. Below, we discuss recent data that supports Boveri’s
original ideas.
Do CIN-enabled gene dosage
changes contribute to cancer?
Gene dosage can influence gene
expression (Fodde and Smits, 2002). For
most genes, with the exception of hap-
loinsufficient genes, loss or mutation of
both copies is required before noticeable
changes in expression occur. Copy num-
ber gains, on the other hand, frequently
lead to increased gene expression.
Classic examples in cancer are highly
amplified genome regions known as
homogeneously staining regions and
double minute chromosomes. These
regions invariably contain genes known
to confer cancer phenotypic advantage
(e.g., proliferation, resistance to therapy)
(Schwab, 1999). While local gene ampli-
fication is undoubtedly the driving
tumorigenic force in some tumors, most
carcinomas do not carry such high-level gene amplifications.
Observations over the past ten years strongly suggest that a
more subtle yet more pervasive form of gene dosage change
may operate in the vast majority of carcinomas (Knuutila et al.,
1998, 1999)
Complicity between structural and numerical CIN in the
Darwinian emergence of defined protumorigenic gene
dosage patterns among related carcinomas
Measurements of relative gene copy number by comparative
genomic hybridization (CGH) have shown that subsets of relat-
ed tumors show similar but not identical patterns of large-scale
gene losses and gains throughout the genome (Knuutila et al.,
1998, 1999). Remarkably, the same tumors show extensive
chromosome fragment transpositions (chromosome scram-
bling) when mapped by spectral karyotyping (SKY) (Schrock et
al., 1996), but they do not share the same (nonrandom) struc-
tural chromosome changes (Figure 2). How could shared gene
dosage changes be reconciled with a multitude of independent
chromosome structural changes?
Changes in gene dosage may be modulated by the pres-
ence of adjacent genes on the same chromosome with antago-
nistic activities (e.g., growth promotion and inhibition), a
condition akin to classic linkage disequilibrium (nonindepen-
dent assortment of genes during cell division). In tumors with
inactivating mutations of a TSG allele, deletion of the normal
allele is required for expression of the TSG phenotype
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Figure 1. Pathways leading to numerical and structural CIN
A: Numerical CIN.
B: Structural CIN.
See text for more details.
Figure 2. Enabling effect of structural chromo-
some instability on gene gains and losses
A: Transposition of chromosome material facili-
tates loss of a TSG. 
B: Transposition of chromosomal material facili-
tates gain of OGs or other growth-promoting
genes. See text for more details.
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(Knudson, 2001).This often occurs in tumors by mitotic deletion
of large chromosome fragments (Figure 1) (Thiagalingam et al.,
2001). However, deletion of the chromosome fragment contain-
ing the normal TSG allele may be encumbered by the presence
of the only remaining normal copy of a nullizygous lethal gene in
its vicinity (telomeric, Figure 2). This situation could arise often,
since every chromosome arm contains hundreds of nullizygous
lethal genes, and any of these could be inactivated in the chro-
mosome arm containing the mutated TSG. Under these condi-
tions, deletion of the normal tumor suppressor allele by loss of
the chromosome arm could occur only if the normal nullizygous
lethal gene is relocated to another chromosome before arm
deletion (Figure 2). This mechanism could also operate when
LOH is the primary event and deletional loss of the other copy of
a TSG is the secondary event (Frei, 1993). In an analogous
manner, accumulation of genes that promote tumor growth (OG
or wild-type allele) may be opposed by strong growth inhibitory
genes in linkage disequilibrium. This opposition could be over-
come if the OG and TSG are first dissociated from each other
during a CIN event and placed into independently segregating
chromosomes at mitoses (no longer in linkage disequilibrium).
Constraints to gene losses and gains by linkage disequilibri-
um suggest a tantalizing model for gene dosage changes in
cancer. The extensive genome scrambling typical of all carcino-
mas may be nothing more than evolution toward a state of “link-
age equilibrium” of cancer genes enabled by CIN and driven by
Darwinian selection. Chromosome transfer experiments in can-
cer cells support this view (Imreh et al., 1997). Thus, the induc-
tion of gene dosage changes may be central to the role of CIN in
cancer development. Although it is generally acknowledged that
extensive genome scrambling is the norm in carcinoma, its
cause(s) are less generally agreed upon. Recent modeling of
carcinoma in mice strongly suggests a dominant mechanism.
Double-strand DNA (dsDNA) breaks and the origins of
scrambled aneuploid genomes
While point mutations arise by misrepair of DNA base damage
or misincorporated DNA bases (Friedberg, 2001), the genome
scrambling typical of carcinomas is most likely catalyzed by
inappropriately repaired dsDNA breaks (Sharpless et al., 2001)
or by eroded telomere ends that are sensed and processed by
cells as dsDNA breaks (Saretzki et al., 1999). Evidence that
supports this idea comes from both dsDNA break repair defi-
ciency syndromes and experimental data in mice with knockout
caretaker genes involved in homologous and nonhomologous
DNA end-joining DNA repair (Maser and DePinho, 2003; Mills et
al., 2003; van Gent et al., 2001).
Unrepaired and unprotected dsDNA breaks, including
exposed telomere ends, are fusogenic and tend to be repaired
by joining to other dsDNA ends. The importance of properly
repaired dsDNA breaks is suggested by the increased inci-
dence of tumors in humans with deficiencies of homologous
recombination or nonhomologous end joining repair, or with
defects in the signaling pathways that sense unrepaired dsDNA
breaks such as in ataxia telangectasia (Meyn, 1997; Shiloh,
2003; Thompson and Schild, 2002). dsDNA breaks or eroded
telomeres repaired to heterologous ends may generate dicen-
tric chromosomes or ring chromosomes that initiate breakage-
fusion-bridge (BFB) cycles (see below, Figure 1). This can lead
to extensive genome remodeling and scrambling characteristic
of carcinoma and cause nonreciprocal translocations, the most
common structural chromosome abnormalities in carcinoma
(Gisselsson, 2003; Lengauer, 2001). Whether BFB cycles gen-
erate defined or random breaks that contribute to cancer is still
an open question. One possibility is that breakpoints are ran-
dom but there is an overrepresentation of those that bring TSG
and OG or TSG and nullizygous lethal genes into linkage equi-
librium (by relocation to different chromosomes and indepen-
dent sorting during mitosis) because they have a selective
advantage. Moreover, the apparent randomness of structural
changes in carcinomas with similar gene dosage patterns may
not reflect random positions of breakpoints that generated the
transposing fragment. Rather, it may result from random trans-
position of the chromosome fragment into any chromosome, as
well as the random position of the breakpoint in the chromo-
some that accepts the transposing fragment. In this manner,
related initiating events might lead to a variety of apparently
unrelated structural changes.
A milestone in experimental human cancer modeling has
been recently achieved by the elegant studies of DePinho and
colleagues (Artandi et al., 2000). Prior to these studies, most
murine cancer models (knockouts, knockins, transgenics)
reproduced some aspects of human lymphomas and sarcomas,
but did not reproduce sporadic human carcinomas well.
DePinho and collaborators, using late-generation telomerase-
null mice, followed emergence of carcinomas with a remarkable
resemblance to human carcinoma. These murine carcinomas
were aneuploid and exhibited extensive CIN, including gains
and losses of chromosomes characteristic of human carcino-
ma. Remarkably, the chromosome regions gained or lost were
syntenic with those gained or lost in orthologous human carci-
nomas (O’Hagan et al., 2002). These findings provide the
strongest experimental evidence, albeit indirect, for defined
(recurrent) abnormal gene dosage patterns in carcinoma devel-
opment. Moreover, epithelial carcinogenesis in telomerase-null
mice was dependent on defective p53 function (Chang et al.,
2001), raising the possibility that the critical role of some check-
point gene mutations (e.g., p53) is to permit emergence of pro-
tumorigenic gene dosage changes. This observation also
highlights the nearly certain interdependence of CIN and critical
gene mutations, since loss of p53 function is permissive for CIN
and gene dosage changes.
The role of mitosis in chromosome breakage and 
missegregtion
Ever since their visualization by von Hansemann more than 100
years ago (von Hansemann, 1890), pathologists have sought
atypical mitoses as hallmarks of malignancy in histological sec-
tions of tumors, yet they rarely pause to consider the implica-
tions of such findings. Cancer mitoses may in fact provide two
key contributions to carcinogenesis. They perpetuate random
break cycles during BFB cycles, leading to extensive genome
scrambling that enables emergence of defined gene dosage
changes. They also induce chromosome missegregation at a
high frequency, thus inducing CIN and gene dosage change
patterns (Figure 1). While BFB cycles appear to be the domi-
nant pathway to structural chromosome changes, it is unclear
what the initiating dsDNA break may be (Figure 2). Clearly, in
telomerase-deficient mice, critically shortened telomeres are
the “dsDNA break” and suggest a very attractive model for
human carcinoma. In human carcinoma, however, this is less
well established, and interstitial DNA breaks may play a signifi-
cant role as well (Difilippantonio et al., 2002). Moreover, while
the mechanism of repair of dsDNA breaks is well understood
(Hoeijmakers, 2001), its contribution to structural chromosome
changes is currently poorly understood. Finally, though the
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nearly universal occurrence of chromosome missegregation in
carcinomas is well established, the dominant mechanisms lead-
ing to it remain poorly defined. Potential contributors include
centrosome dysfunction, anaphase checkpoint malfunction,
and cytokinesis failure (Figure 1) (Jallepalli and Lengauer,
2001; Pihan and Doxsey, 1999). Future studies will be required
to determine whether gene dosage changes alone can repro-
duce phenotypic characteristics of carcinomas. This may pose
some difficulties, since large-scale gene dosage changes are
poorly tolerated by normal cells and invariably lead to check-
point activation and cell cycle arrest (Andreassen et al., 2001).
In conclusion, recent results in murine carcinoma models
suggest that expression of the cancer phenotype in carcinomas
invariably involves gene dosage changes as well as intragenic
mutations. Most gene dosage changes occur via chromosome
transpositions catalyzed by chromosome BFB cycles coupled to
mitotic chromosome missegregation. At least some mutations
are critically permissive for gene dosage changes. The genome
plasticity generated by these mechanisms may facilitate not
only early tumor development but also tumor evolution toward
enhanced growth, loss of normal apoptotic mechanisms, and
resistance to therapy.
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